



# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/849,809	05/04/2001	Mark W. Perlin	PERLIN-10	8918	
7590 03/02/2006			EXAMINER		
Ansel M. Schwartz			SMITH, CAROLYN L		
Attorney at Lav Suite 304	V	ART UNIT	PAPER NUMBER		
201 N. Craig St		1631			
Pittsburgh, PA 15213			DATE MAILED: 03/02/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applica	ition No.	Applicant(s)				
Office Action Summary		09/849		PERLIN, MARK	W.			
		Examin	er	Art Unit				
		Carolyn	L. Smith	1631				
Period fo	The MAILING DATE of this commun			ith the correspondence a	ddress			
A SH WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE Manions of time may be available under the provision SIX (6) MONTHS from the mailing date of this come to period for reply is specified above, the maximum so re to reply within the set or extended period for reply reply received by the Office later than three months ed patent term adjustment. See 37 CFR 1.704(b).	MAILING DATE OF sof 37 CFR 1.136(a). In no munication. tatutory period will apply and will, by statute, cause the a	THIS COMMUNI event, however, may a d will expire SIX (6) MON application to become A	CATION. reply be timely filed  NTHS from the mailing date of this of BANDONED (35 U.S.C. § 133).				
Status								
1)⊠	Responsive to communication(s) fil	ed on <i>15 December</i>	2005					
2a)□	Responsive to communication(s) filed on <u>15 December 2005</u> .  This action is <b>FINAL</b> .  2b) This action is non-final.							
3)								
ت(۵	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposit	·			,				
Disposition of Claims								
,—	Claim(s) <u>1-4,8,9,11 and 12</u> is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.							
	Claim(s) is/are allowed.							
	·							
•	)⊠ Claim(s) <u>1-4,8,9,11 and 12</u> is/are rejected. )⊡ Claim(s) is/are objected to.							
•	Claim(s) are subject to restri	ction and/or election	requirement					
ا ا(٥	Claim(s) are subject to restri	ction and/or election	rrequirement.					
Applicat	ion Papers							
9)☐ The specification is objected to by the Examiner.								
10)[	The drawing(s) filed on is/are	: a) ☐ accepted or	b)☐ objected to	by the Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority (	under 35 U.S.C. § 119							
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>								
Attachmen	• •							
	e of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (	PTO-948)		Summary (PTO-413) (s)/Mail Date				
3) 🔲 Infon	mation Disclosure Statement(s) (PTO-1449 or No(s)/Mail Date		_	Informal Patent Application (PT	O-152)			

# **DETAILED ACTION**

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission, filed 12/15/05, has been entered.

Amended claims 1 and 11, filed 12/15/05, are acknowledged.

Claims herein under examination are 1-4, 8-9, and 11-12.

# Claim Rejections - 35 USC § 112, first paragraph

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-4, 8-9, and 11-12 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

There does not appear to be adequate written support for the phrase "or higher" in amended claims 1 (line 8) and 11 (line 10). Applicant points to support on page 21, lines 1-6, of the specification. This section of the specification fails to mention second, third, and higher

Art Unit: 1631

dimensions. Because introduction of the phrase "or higher" does not appear to have written support, this phrase is considered to be NEW MATTER. Claims 2-4, 8-9, and 12 are also rejected due to their dependency from claims 1 and 11.

# Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-4, 8-9, and 11-12 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1 (lines 6-9) and 11 (lines 8-11) recite the limitation "detecting a total amount of label present in the collection to produce a measurement that is determined without performing a one or higher dimensional DNA size separation on the products" which is vague and indefinite. First, it is unclear what this step (of claim 1) and means (of claim 11) is actually claiming. It is unclear if the "amount" is the "measurement", if one is taking the amount to calculate a measurement, or various other scenarios. Second, it is unclear in what manner the "without performing" phrase is limiting these claims. Is the "without performing" limiting the measurement, the detecting, some sort of calculation, or the entire method? Clarification of this issue via clearer claim wording is requested. Claims 2-4, 8-9, and 12 are also rejected due to their dependency from instant claims 1 and 11.

Claim 8 recites the limitation "is used for criminal justice applications" which is vague and indefinite. This limitation is a passive step. It is unclear what active method step is intended

to be represented by this limitation. It is also unclear in what manner (i.e. steps) the information is to be applied to the criminal justice applications. Clarification of this issue via clearer claim wording is requested.

Claim 9 recites the limitation "is used in conjunction with" which is vague and indefinite.

This limitation is a passive step. It is unclear what active method step is intended to be represented by this limitation. For example, are the data intended to be mathematically combined with the database for mathematical additions, are the data intended to be combined with the database to undergo statistical analysis, or are the data combined with the database merely to update or store more data? Clarification of this issue via clearer claim wording is requested.

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-4 and 11 are rejected under 35 U.S.C. 102(b) as being anticipated by Cheeseman (US 5,302,509).

Cheeseman discloses a method of sequencing polynucleotides (title and abstract).

Cheeseman discloses amplifying a nucleic acid sample by polymerase chain reaction techniques to create many DNA molecules (col. 3, fourth and fifth paragraphs) which represents the amplifying step (a) of instant claims 1 and 11. Cheeseman discloses using a primer bound to the

DNA and extending the growing oligonucleotide chain with four fluorescently labeled 3'blocked nucleotide triphosphates (NTPs) (col. 3, line 65 to col. 4, line 22 and col. 4, lines 63-68) which represents the extending a sequencing primer bound to the DNA product in the presence of terminating nucleotide analogs to produce a collection of labeled nucleic acid products, as stated in step 1(b) of instant claims 1 and 11. Cheeseman discloses each of the NTPs types (A, G, C, and T NTPs) will be labeled differently so as to be distinguishable by fluorescent spectroscopy or other optical means (col. 4, lines 5-10), identifying the labeled NTP in the DNA strand and repeating these steps until labeled NTPs can no longer be added (col. 2, lines 52-56 and 64-68) wherein the whole sequencing cell (chamber) with optical detection on a planar integrated optical system can be produced by photolithographic means and the planar optics allows many sequencing cells to be produced on the same substrate and illuminated by the same light source (col. 6, lines 58-66) which represents the detecting a total amount of label present in the collection to produce a measurement that is determined without performing a one or higher dimensional DNA size separation on the products, as stated in step (c) of instant claims 1 and 11. Cheeseman discloses repeating the exposure of the four labeled NTPs to the sequence to add another base at each cycle to the growing oligonucleotide thereby identifying the next base until identification is complete (col. 7, third paragraph) with a DNA length example (col. 7, line 54) which represents combining a plurality of measurements to determine the DNA sequence information about the sample (as stated in step (d) of instant claims 1 and 11) as well as DNA sequence information corresponding to the length and plurality of bases in the DNA sequence (as stated in instant claims 3 and 4). Cheeseman discloses only one of the four NTP types being added at a time and read by its fluorescence (col. 5, lines 28-31), adjusting concentrations of

Page 5

Application/Control Number: 09/849,809

Art Unit: 1631

bound NTPs with DNA such that there is a sufficient number of fluorescent molecules for optical detection (col. 5, lines 41-48) as well as dye concentrations in small areas to improve detection of fluorescence by improving signal-to-noise ratio (col. 6, lines 40-46) which represents each label measurement corresponds to an amount of terminating nucleotide, as stated in instant claim 2. Cheeseman discloses a solid-supported DNA, planar integrated optical system, optical fiber attached to DNA, fluorescent output detection by PIN photodiodes, and flow system (col. 6, lines 30-68; col. 7, fourth and fifth paragraphs) which represent the system for nucleic acid sequencing, as stated in instant claim 11.

Thus, Cheeseman anticipates instant claims 1-4 and 11.

Applicant's arguments with respect to the 35 USC 102(b) rejection have been considered but are most in view of the new ground(s) of rejection.

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 8, 9, and 12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cheeseman (US 5,302,509) as applied to claims 1-4 and 11 above; taken in view of Schumm et al. (US 20020012924).

Application/Control Number: 09/849,809

Art Unit: 1631

Cheeseman discloses the limitations of instant claims 1-4 and 11 as stated in the 102 rejection above. Cheeseman does not describe using DNA sequence information for criminal justice applications (instant claim 8), DNA information used in conjunction with a DNA database of genetic polymorphisms (instant claim 9), a PCR thermocycler (instant claim 12), or a computing device with a memory (instant claim 12).

Schumm et al. describe DNA sequencing with PCR including using a thermocycler (paragraphs 0089-0090), as stated in instant claim 12. Schumm et al. describe using DNA profiling for criminal justice applications (paragraph 0013), as stated in instant claim 8. Schumm et al. describe using DNA information with databases including genetic polymorphism data (paragraph 0012), as stated in instant claim 9. Schumm et al. describe using an ABI 377 Sequencer including putting data into a database using computer software (paragraph 0096) and scanning and analyzing for polymorphisms using Hitachi FMBIO fluorescent scanner with accompanying software (paragraph 0100) which represents a computing device with memory, as stated in instant claim 12.

Schumm et al. state DNA typing is commonly employed to identify the source of blood, saliva, semen, and other tissue found at a crime scene (paragraph 0004). Cheeseman state that his DNA sequencing method requires only small quantities of DNA for high sensitivity detection (col. 1, last paragraph). It would have been obvious to the person of ordinary skill in the art at the time the invention was made to analyze the small quantities for DNA sequencing, as stated by Cheeseman, with the databases and computing devices for criminal justice applications, as stated by Schumm et al., because this offers significant improvement over existing technology, bringing increased power and precision to DNA profiling for linkage analysis, criminal justice,

Application/Control Number: 09/849,809

Art Unit: 1631

paternity testing, and other forensic and medical uses, as stated by Schumm et al. (paragraph 0013). The person of ordinary skill in the art at the time the invention was made would have been motivated to make this modification in order to eliminate ambiguity in short DNA sequences, as stated by Cheeseman (col. 2, first paragraph) in forensic analysis which often require determination of whether more than one source of DNA sample is present, as stated by Schumm et al. (paragraph 0010). One of ordinary skill in the art would have expected success as both Cheeseman and Schumm et al. sequence DNA using PCR methods and Schumm et al. states their ability to identify and analyze particular polymorphic loci of DNA of various types, including single-stranded and double-stranded DNA from a variety of different sources (paragraph 0013).

Thus, Cheeseman in view of Schumm et al. make obvious the instant invention.

Applicant's arguments with respect to the 35 USC 103(a) rejection have been considered but are most in view of the new ground(s) of rejection.

## Conclusion

No claim is allowed.

Papers related to this application may be submitted to Technical Center 1600 by facsimile transmission. Papers should be faxed to Technical Center 1600 via the PTO Fax Center. The faxing of such papers must conform to the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)

Art Unit: 1631

(See 37 CFR §1.6(d)). The Central Fax Center number for official correspondence is (571) 273-8300.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carolyn Smith, whose telephone number is (571) 272-0721. The examiner can normally be reached Monday through Thursday from 8 A.M. to 6:30 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, can be reached on (571) 272-0718.

Any inquiry of a general nature or relating to the status of this application should be directed to Legal Instruments Examiner Tina Plunkett whose telephone number is (571) 272-0549.

February 21, 2006

Carolyn Smith Examiner

Art Unit 1631